Research has shown that patients with inflammatory bowel disease, including ulcerative colitis, treated with TNF-alpha blockers have a lower antibody response and a shorter duration of immunity than those who receive integrin receptor antagonists, such as Entyvio (vedolizumab), or no medication at all.
Read More
Statin Use May Lower Risk of Colorectal Cancer in Patients with Ulcerative Colitis
September 8th 2023In an observational cohort study published in the September 2023 issue of The Lancet, Jiangwei Sun, Ph.D., from the Karolinska Institutet in Stockholm, Sweden, and his colleagues compared statin users with non-statin users to determine the risk of colorectal cancer in patients with IBD.
Read More
Interleukin-2 Found to Be a Promising Pathway to Treat Ulcerative Colitis
August 7th 2023A small, open-label study seeds the idea that IL-2 in low doses might be another avenue for treating ulcerative colitis. Low doses may bolster anti-inflammatory T regulatory cells (Tregs) that are believed to lack sufficient expansion in the disease.
Read More
Gene Replacement Therapy for Duchenne Muscular Dystrophy: The Race Is On
May 12th 2023Sarepta Therapeutics and Roche are competing with Pfizer to develop the first gene replacement therapy for Duchenne muscular dystrophy. Sarepta and Roche are ahead after the FDA put a clinical hold on Pfizer’s product.
Read More
Entyvio Found To Be Effective at Relieving Chronic Pouchitis After UC Surgery
April 19th 2023Patients treated with the gut-selective monoclonal antibody were three times more likely to achieve remission of inflammation of ileal pouch-anal anastomosis, an alternative to a life-long colostomy bag after colectomy.
Read More